会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Bis(thio-hydrazide amide) salts for treatment of cancers
    • 用于治疗癌症的双(硫代酰肼)酰胺盐
    • US08048925B2
    • 2011-11-01
    • US12871587
    • 2010-08-30
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • A61K31/16
    • C07D305/14C07C327/56C07C2601/02
    • Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.
    • 公开了由结构式(I)表示的双(硫代 - 酰肼酰胺)二醛:Y是共价键或取代或未取代的直链烃基。 R 1 -R 4独立地为-H,脂族基团,取代的脂族基团,芳基或取代的芳基,或者R 1和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4 与它们所键合的碳原子和氮原子一起形成任选地与芳环稠合的非芳族杂环。 Z是-O或-S。 M +是药学上可接受的一价阳离子,M2 +是药学上可接受的二价阳离子。 还公开了包含上述双(硫代 - 酰肼酰胺)二盐的药物组合物。 进一步公开的是用癌症治疗受试者的方法。 所述方法包括施用有效量的上述双(硫代 - 酰肼酰胺)二盐的步骤。
    • 5. 发明授权
    • Bis(thio-hydrazide amide) salts for treatment of cancers
    • 用于治疗癌症的双(硫代酰肼)酰胺盐
    • US07795313B2
    • 2010-09-14
    • US12503661
    • 2009-07-15
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • A61K31/16
    • C07D305/14C07C327/56C07C2601/02
    • Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation. Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.
    • 公开了由结构式(I)表示的双(硫代 - 酰肼酰胺)二醛:Y是共价键或取代或未取代的直链烃基。 R 1 -R 4独立地为-H,脂族基团,取代的脂族基团,芳基或取代的芳基,或者R 1和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4 与它们所键合的碳原子和氮原子一起形成任选地与芳环稠合的非芳族杂环。 Z是-O或-S。 M +是药学上可接受的一价阳离子,M2 +是药学上可接受的二价阳离子。 还公开了包含上述双(硫代 - 酰肼酰胺)二盐的药物组合物。 进一步公开的是用癌症治疗受试者的方法。 所述方法包括施用有效量的上述双(硫代 - 酰肼酰胺)二盐的步骤。
    • 6. 发明授权
    • BIS (thio-hydrazide amide) salts for treatment of cancers
    • 用于治疗癌症的BIS(硫代酰肼)酰胺盐
    • US07579503B2
    • 2009-08-25
    • US12148312
    • 2008-04-18
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • C07C327/38A61K31/16
    • C07D305/14C07C327/56C07C2601/02
    • Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.
    • 公开了由结构式(I)表示的双(硫代 - 酰肼酰胺)二醛:Y是共价键或取代或未取代的直链烃基。 R 1 -R 4独立地为-H,脂族基团,取代的脂族基团,芳基或取代的芳基,或者R 1和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4 与它们所键合的碳原子和氮原子一起形成任选地与芳环稠合的非芳族杂环。 Z是-O或-S。 M +是药学上可接受的一价阳离子,M2 +是药学上可接受的二价阳离子。 还公开了包含上述双(硫代 - 酰肼酰胺)二盐的药物组合物。 进一步公开的是用癌症治疗受试者的方法。 所述方法包括施用有效量的上述双(硫代 - 酰肼酰胺)二盐的步骤。
    • 9. 发明授权
    • Bis(thio-hydrazide amide) salts for treatment of cancers
    • 用于治疗癌症的双(硫代酰肼)酰胺盐
    • US07385084B2
    • 2008-06-10
    • US11157213
    • 2005-06-20
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • Keizo KoyaLijun SunElena KostikFarid VaghefiShoujun ChenNoriaki TatsutaGuiqing LiangTakayo InoueZhi-Qiang Xia
    • C07C327/38A61K31/16
    • C07D305/14C07C327/56C07C2601/02
    • Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.
    • 公开了由结构式(I)表示的双(硫代 - 酰肼酰胺)二醛:Y是共价键或取代或未取代的直链烃基。 R 1 -R 4独立地是-H,脂族基团,取代的脂族基团,芳基或取代的芳基,或R 1, SUB和R 3与它们所键合的碳原子和氮原子一起,和/或R 2和R 4结合在一起 与其键合的碳原子和氮原子形成任选地稠合到芳香环的非芳族杂环。 Z是-O或-S。 M + +是药学上可接受的一价阳离子,M 2 +是药学上可接受的二价阳离子。 还公开了包含上述双(硫代 - 酰肼酰胺)二盐的药物组合物。 进一步公开的是用癌症治疗受试者的方法。 所述方法包括施用有效量的上述双(硫代 - 酰肼酰胺)二盐的步骤。